Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2013

Knome, RTG to Co-Distribute Genomic Analysis, Interpretation Systems

  • Knome will integrate the Real Time Genomics (RTG) Variant platform into every shipment of its knoSYS™100 interpretation system through a new agreement between the two companies. According to a Knome statement, “the agreement enables customers to easily purchase the RTG analytics engine as an upgrade to the system.” Further, the company said that “the product will combine two…commercial platforms to deliver end-to-end genome analytics and interpretation with superior accuracy and speed.” Financial terms of the deal were not disclosed.

    The firm added that through this partnership, knoSYS customers can purchase the RTG platform directly through Knome sales reps.

    “Concomitant with that demand [for genome interpration] is the need for accurate and easy-to-use industrial grade analysis that meets expectations of clinical accuracy,” Wolfgang Daum, Knome CEO said in a statement. “The RTG platform is both incredibly fast and truly differentiating to customers doing family studies, and we are excited to add such a powerful platform to the knoSYS ecosystem.”

    Added Real Time Genomics’ Steve Lombardi: “The Knome system is a perfect complementary channel to further expand our commercial effort to bring the RTG platform to market.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »